Biomarkers of Cockroach Sublingual Immunotherapy 2

Inclusion Criteria

• •Have a history of perennial allergic rhinitis, asthma, or both, before study entry. For those with asthma:
• •1. a diagnosis of asthma will be defined as a report by the participant that they have had a clinical diagnosis of asthma made by a physician over a year ago
• •2. the participant's asthma must be well controlled as defined by: ii. a forced expiratory volume at one second (FEV1) greater than or equal to 80% predicted value with or without controller medication ii. albuterol use for no more than 3 days per week in each of the previous 2 weeks for asthma symptoms (not including exercise prophylaxis)
• •Are sensitive to German cockroach (Blattella germanica) as documented by a positive (\>/=3 mm greater than negative control) skin prick test result and detectable German cockroach specific IgE (\>/=0.35 kUA/L)
• •Have no known contraindications to therapy with glycerinated German cockroach allergenic extract or placebo
• •Parent or legally authorized representative (LAR) of child is willing to sign the written Informed Consent prior to initiation of any study procedure
• •Do not primarily speak English
• •Plan to move from the area during the study period
• •Have a history of idiopathic anaphylaxis or anaphylaxis grade 2 or higher
• •Have unstable angina, significant arrhythmia, uncontrolled hypertension, history of autoimmune disease, or other chronic or immunological diseases that in the opinion of the investigator might interfere with the evaluation of the investigational agent or pose additional risk to the patient (e.g., gastrointestinal disease, gastroesophageal reflux disease, chronic infections, scleroderma, hepatic, and gallbladder disease)
• •Are using tricyclic antidepressants or beta-adrenergic blocker drugs (either oral and/or topical route\[s\] of administration)